Everest Group, Ltd. (NYSE:EG) Q1 2024 Results Conference Call April 30, 2024 8:00 AM ET Company Participants Matt Rohrmann – Head, IRJuan Andrade – President, CEOMark Kociancic – EVP, CFOJim Williamson – EVP, COO Conference Call Participants David Motemaden – Evercore ISIBrian Meredith – UBSMichael Zaremski – BMOJosh Shanker – Bank of AmericaElyse Greenspan –…
JHVEPhoto Investment Thesis Everest Group (NYSE:EG) is a reinsurance and primary insurance provider. EG is embarking on global expansion in the primary insurance market, attempting to capture the nearly $1 trillion in total addressable market. Additionally, the strong reinsurance market will continue to provide significant tailwinds until at least fiscal year 2025. Across the whole…
MadamLead Deals and Financings Shanghai Everest Medicines (HK: 1952) acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences (KZR) of South San Francisco in a deal worth $132.5 million (see story). The candidate, zetomipzomib, is a first-in-class, selective inhibitor of the immunoproteasome that is expected to treat several autoimmune diseases…
Everest Group, Ltd. (NYSE:EG) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Company Participants Matthew Rohrmann – Senior Vice President, Head of Investor Relations Juan Andrade – President and Chief Executive Officer Mark Kociancic – Executive Vice President and Chief Financial Officer James Williamson – Executive Vice President, Group Chief Operating Officer…